Skip to Content

Ellevest Inc. sells 3,170 AstraZeneca PLC shares (NASDAQ:AZN)

Ellevest Inc. sells 3,170 AstraZeneca PLC shares (NASDAQ:AZN)

According to the most recent Form 13F filing that Ellevest Inc. submitted with the Securities and Exchange Commission, the investment firm’s holdings in AstraZeneca PLC (NASDAQ: AZN) were reduced by 20.7% during the third quarter (SEC). Following the transaction that took place during the period, the company now holds 12,121 shares of the company’s stock, bringing the total number of shares owned by the business to 12,121. The most recent report that Ellevest Inc. was required to file with the Securities and Exchange Commission indicated that the value of the company’s holdings in AstraZeneca was $665,000.

A number of other hedge funds have followed suit and decreased the total amount of money they have invested in the company. Better Money Decisions LLC purchased a brand new stake in AstraZeneca valued at $25,000 during the second quarter. As of the end of the first quarter, Parkside Financial Bank & Trust had a total ownership stake in AstraZeneca that was 4,875.0% higher than it had been before the quarter. Parkside Financial Bank & Trust is the owner of 398 shares in the company, which have a value of $26,000 due to the purchase of an additional 390 shares in the company during the most recent quarter. The transaction took place during the most recent quarter. The amount of $28,000 was spent by HHM Wealth Advisors LLC during the second quarter on the acquisition of a brand new position in AstraZeneca. The investment company Hazlett Burt & Watson Inc. increased the amount of AstraZeneca stock owned by 129.5% during the third quarter of the fiscal year. The most recent quarter saw Hazlett Burt & Watson Inc. acquire an additional 290 shares of the company’s stock, bringing their total number of shares owned in the company up to 514, with a value of $28,000. This was the most recent quarter. Last but not least, during the first three months of the year, Fairfield Bush & Co. established a new stake in AstraZeneca that consists of approximately $28,000 worth of shares. Currently, institutions hold 16.42% of the total equity in the company.

The price of an individual share of AstraZeneca fell by $0.12 during trading on Tuesday, bringing the total cost of the stock to $70.96. The volume of typically traded shares is 3,665,615, but the company only traded 114,638 of them today. This is a significant drop from the typical volume. The stock’s price has reached $62.64 on its simple moving average for the past 200 days, while the price has reached $67.61 on its simple moving average for the past 50 days. During the previous year, the price of AstraZeneca PLC has moved in a range that has spanned from $52.65 to $72.12, with a low of $52.65 and a high of $72.12. The company’s market capitalization is currently valued at $219.89 billion. It has a price-to-earnings ratio of 106.09, a price-to-earnings-growth ratio of 1.30, and a beta value of 0.53. All of these metrics do an excellent job of describing the company. The quick ratio is 0.61, the current ratio is 0.81, and the debt-to-equity ratio is 0.65. All of these numbers are relative to the total amount of debt. All these figures should be interpreted in light of the overall sum owed.

AstraZeneca (NASDAQ: AZN) announced the publication of its quarterly results on November 10, which was a Thursday. The company came in with quarterly earnings of $0.84 per share, which was $0.07 more than the consensus estimate of $0.77 per share from industry analysts. AstraZeneca had a return on equity of 29.40% and a net margin of 4.52% for the company overall. The company’s quarterly sales came in at $10.98 billion, which is in line with the projections of industry experts, who anticipated sales of the same amount. Earnings of $3.33 per share are what equity research professionals anticipate AstraZeneca PLC will generate during the current fiscal year. These projections were made for the company.

AZN shares have received a lot of attention as of late from various research analysts. After receiving a grade of “c” in a previous report from TheStreet, the pharmaceutical company AstraZeneca was given an “a” in a report released on Monday, December 5. JPMorgan Chase & Co. disclosed in a report made public on Tuesday, January 3, that the price objective they have established for AstraZeneca shares has increased from £125 ($152.53) to £135 ($164.73). Berenberg Bank stated in a research article released on Wednesday, October 19, that the price objective they have set for AstraZeneca shares has decreased from GBX 120 ($1.46) to GBX 118 ($1.44) since it was originally set. StockNews.com first covered a research report on AstraZeneca shares on October 12 after the website published it. This publication began the website’s coverage of the company’s shares. They suggested that an interested party purchase the company.

Last but not least, on January 5 of this year, BMO Capital Markets published a research note that covered AstraZeneca shares as part of the expansion of the company’s coverage. They gave the business an “outperform” rating out of five stars. Six different financial experts have given the company their endorsement to purchase the stock, five different analysts have given the company their endorsement to hold the stock, and one different analyst has given their endorsement to sell the stock. According to information from Bloomberg.com, the stock is currently rated “Hold” on average, and market analysts have determined an average price target of $9,509.78.

AstraZeneca PLC is a biopharmaceutical company specializing in the research and development of prescription medications and their manufacture, distribution, and marketing. Crestor, Evrenzo, Farxiga, Bydureon, Byetta, BCise, Brilinta, and Brilique are some of the oncology-related drugs the company manufactures. Other oncology-related medications include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex.

Are you curious about the various hedge funds that control AZN and want to learn more about them? By going to HoldingsChannel.com, you can research the most recent 13F filings and insider transactions for AstraZeneca PLC (NASDAQ: AZN).

Leave a comment

Your email address will not be published. Required fields are marked *